Dexmedetomidine inhibits inflammation and angiogenesis and alleviates esophageal cancer progression through ITGA6/PI3K/AKT pathway: Dexmedetomidine inhibits esophageal cancer progression. Indian J Exp Biol. 2026;64(01):15-32. doi:10.56042/ijeb.v64i01.22881